… erlotinib and bevacizumab superior to erlotinib alone to treat epidermal growth factor receptor
(EGFR)–mutant non–small cell lung cancer… erlotinib alone, the combination of erlotinib and …

… compare the efficacy of erlotinib plus bevacizumab with erlotinib alone in patients with EGFR…
and erlotinib had improved progression-free survival compared with patients given erlotinib …

… Sorafenib, an oral multikinase inhibitor, has shown preliminary activity in non–small-cell lung
cancer (NSCLC). Patients with advanced NSCLC were treated with erlotinib with or without …

… Bevacizumab and erlotinib target different tumour growth pathways with little overlap in their
… activity of erlotinib plus bevacizumab for recurrent or refractory non-small-cell lung cancer (…

… erlotinib may enhance antitumor activity compared with either agent alone in non–small-cell
lung cancer (NSCLC), based on the importance of the signaling pathways involved in tumor …

… inhibitor erlotinib in athymic nude mice bearing non-small cell lung cancer (NSCLC) xenograft
models. Immunohistochemistry determined the HER1/EGFR status of the NSCLC tumor …

… vomiting 32,33 ) is distinct from that of erlotinib. Here we report the results of a phase … (Tarceva
Lung Cancer Investigation [TALENT]) of cisplatin and gemcitabine with or without erlotinib …

… growth factor monoclonal antibody, and erlotinib, a reversible, orally available … of non–small-cell
lung cancer (NSCLC). A single-arm phase I and II study of bevacizumab plus erlotinib …

… Inhibition of epidermal growth factor receptor (EGFR) has become an important target in the
treatment of advanced non-small cell lung cancer (NSCLC). Erlotinib and gefitinib, two small …

… activating EGFR mutation-positive non-small-cell lung cancer (NSCLC), median progression…
the combination of erlotinib and bevacizumab compared with erlotinib alone in patients with …